Utility of Hydroxychloroquine medicine as a supportive treatment for breast cancer patients

Hydroxychloroquine in neoadjuvant treatment of triple negative breast cancer - NIL

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2023/11/059909

Enrollment

Registered

2023-11-16

Start date

Unknown

Completion date

Unknown

Last updated

2023-12-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: C509- Malignant neoplasm of breast of unspecified site

Interventions

Intervention1: Hydroxychloroquine (Brand Name-HCQS): Hydroxychloroquine (HCQ) DOSAGE FORM: 200 mg tablet, oral route DOSAGE: 200 mg BID by mouth, for a total daily dose of 400 mg FREQUENCY: HCQ is tak

Eligibility

Inclusion criteria

Inclusion criteria: Patients diagnosed with triple negative breast cancer and receiving neoadjuvant chemotherapy (NACT). Age more than 18yrs Performance Status less than or equal to 2

Exclusion criteria

Exclusion criteria: •Metastatic triple negative breast cancer. •Patients taking alternative therapies concurrently. •Receipt of hydroxychloroquine (HCQ) within the past 6 months. •History of allergic reactions attributed to compounds of similar chemical or biologic composition to HCQ

Design outcomes

Primary

Measure	Time frame
1.Demographiccharacteristics,clinicalpresentations, histopathologyreports, diagnostic results, and treatment details. 2.Genomic and proteomic analysis will be carried out. 3.Change in Prostate Apoptosis Response-4 (PAR-4) Levels. 4.PAR-4 levels measured via serum or plasma blood sample. Timepoint: 0 weeks, 2 weeks and at the end of treatment	—

Secondary

Measure	Time frame
nilTimepoint: nil	—

Countries

India

Contacts

Public ContactDr. Ananth Pai

Kasturba Medical College and Hospital

ananth.pai@manipal.edu9880239139

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026